Brought to you by 
CytomX pens Probody deal with Bristol
27 Oct 2021
Executive Summary
CytomX Therapeutics Inc. (next-generation, targeted antibodies) licensed Bristol-Myers Squibb Co. exclusive worldwide rights to discover, develop, and sell Probodies interacting with up to four immuno-oncology targets, including cytotoxic T-lymphocyte antigen-4 (CTLA-4).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
CytomX pens Probody deal with Bristol
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice